The type 2 diabetes therapy market will rapidly expand over our 2016-2026 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the most rapid growth are the sodium/glucose cotransporter 2 ( SGLT 2) inhibitors—due to the cardiovascular ( CV ) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 ( GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and semaglutide. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.
Following Jardiance’s positive CV results, will SGLT 2 inhibitors surpass the dipeptidyl peptidase ( DPP ) IV inhibitors as the most valuable oral drug class?
Boosted by positive CV data, will Victoza continue to lead the GLP 1 receptor agonists in the face of once-weekly agents such as Trulicity and semaglutide?
Will investments by the pharmaceutical industry in novel FDC s such as Xultophy and Soliqua reap rewards?
What do key opinion leaders think about emerging therapies such as Fiasp, Lusduna, ITCA-650, and semaglutide?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.